Racemic Drug
Paired Concept:
Chiral Switch
Definition: A pharmaceutical product that contains equal amounts (1:1 ratio) of both enantiomers of a chiral drug,
forming a racemic mixture (racemate).
Context: Many chiral drugs were originally developed and marketed as racemates because synthesizing or separating
individual enantiomers was technically challenging and costly. However, the two enantiomers in a racemic drug may differ
significantly in pharmacological activity, pharmacokinetics, metabolism, toxicity, or side-effect profiles. Advances in
chiral synthesis and regulatory requirements have led to the development of several single-enantiomer versions of
previously marketed racemic drugs, a process known as a chiral switch.
Example: Ibuprofen is marketed as a racemic drug containing both R- and S-ibuprofen. The S-enantiomer is primarily
responsible for the anti-inflammatory activity, while the R-enantiomer undergoes partial metabolic conversion to the
active S-form in vivo.
Related Terms: Racemate, Enantiomer, Enantiopure Drug, Chiral Switch, Eutomer, Distomer, Stereoselectivity.
Reference: Ariens, E. J. (1984). "Stereochemistry, a Basis for Sophisticated Nonsense in Pharmacokinetics and
Clinical Pharmacology." European Journal of Clinical Pharmacology, 26, 663-668; Smith, S. W. (2009). "Chiral Toxicology:
It's the Same Thing... Only Different." Toxicological Sciences, 110(1), 4-30; Nguyen, L. A., He, H., & Pham-Huy, C.
(2006). "Chiral Drugs: An Overview." International Journal of Biomedical Science, 2(2), 85-100; International Union of
Pure and Applied Chemistry. Compendium of Chemical Terminology (Gold Book) - Definitions of racemate, enantiomer, and
chirality-related terms.
Key Distinction
| Term |
Characteristic |
| Racemic Drug |
Contains equal amounts of both enantiomers (50:50); ee = 0%. |
| Enantiopure Drug |
Contains only one enantiomer; ee ? 100%. |
| Enantioenriched Drug |
Contains one enantiomer in excess over the other; 0% < ee < 100%. |
| Chiral Switch |
Development of a single-enantiomer drug from a previously marketed racemic drug. |
Key Insight: A racemic drug is not necessarily inferior to an enantiopure drug. In some cases, both enantiomers
contribute
beneficially to therapeutic activity, whereas in others one enantiomer may be inactive or associated with adverse
effects. Consequently, the choice between a racemate and a single-enantiomer drug depends on scientific, clinical, and
regulatory considerations.
